RxDoctor Payments Data

Ashley Patel

Psychiatric/Mental Health · Longview, TXNPI 1174292056

Payments from drug & device makers

$10,837in general payments, 2019–2025

Across 591 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • Alkermes, Inc.$1K
  • Vanda Pharmaceuticals Inc.$956
  • Teva Pharmaceuticals USA, Inc.$857
  • AbbVie$825
  • plus $4K from 21 others

What the payments were for

  • Food & beverage$10,74099%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,837 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate28$235,459
RexultiBrexpiprazole38$56,064
VraylarCariprazine Hcl31$47,897
CaplytaLumateperone Tosylate17$31,831
TrintellixVortioxetine Hydrobromide34$20,647
LybalviOlanzapine/Samidorphan Malate11$18,540
SecuadoAsenapine11$16,211
QuviviqDaridorexant Hcl20$10,372
Aripiprazole26$2,280
Ziprasidone Hcl13$1,459
Buspirone Hcl34$686
Olanzapine36$672
Sertraline Hcl65$640
Duloxetine Hcl23$634
Mirtazapine16$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,332$235,45928 claims
Otsuka America Pharmaceutical, Inc.Rexulti$501$56,06438 claims
AbbVieVraylar$825$47,89731 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$529$31,83117 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$86$20,64734 claims
Alkermes, Inc.Lybalvi$1,085$18,54011 claims
Idorsia Pharmaceuticals US IncQuviviq$245$10,37220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →